Babar Ghias - 17 Dec 2025 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role: Chief Financial Officer
Signature: /s/ Alane P. Barnes, by power of attorney
Issuer symbol: BCRX
Transactions as of: 17 Dec 2025
Net transactions value: $0
Form type: 4
Filing time: 19 Dec 2025, 16:11:18 UTC
Previous filing: 28 Jul 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Ghias Babar	Chief Financial Officer	4505 EMPEROR BLVD., SUITE 200, DURHAM	/s/ Alane P. Barnes, by power of attorney	19 Dec 2025	0002076862

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BCRX	Common Stock	Award	$0	+121,700	+83%	$0.000000	268,700	17 Dec 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BCRX	Emp. Stock Option (Right to Buy)	Award	$0	+355,050		$0.000000	355,050	17 Dec 2025	Common Stock	355,050	$7.13	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Annual award of restricted stock units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
F2	Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.